US-based life sciences firm Emergent BioSolutions has secured around $23m for the development of a new multi-drug auto-injector to deliver nerve agent antidote.

Being developed for the country’s Department of Defense (DoD), the new device will be used for intramuscular self or buddy-administration of antidotes in military environments, as well as during civilian emergencies.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

DoD awarded Emergent with a five-year agreement through its Medical CBRN Defense Consortium (MCDC), which is an initiative within the department’s Joint Programme Executive Office for Chemical and Biological Defense.

The agreement requires Emergent to develop the injector and evaluate the final device in various studies to validate its consistent manufacture, functionality and usability.

Emergent BioSolutions business operations executive vice-president Adam Havey said: “Ease of use and rapid delivery of antidotes are critical features of auto-injectors that are intended to mitigate the health effects of nerve agent exposure.

“Emergent will also be responsible for the regulatory activities associated with obtaining approval for the device from the US Food and Drug Administration (FDA).”

“Emergent’s device seeks to satisfy the requirements of the DoD for a novel auto-injector platform technology.”

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Under the agreement, Emergent will also be responsible for the regulatory activities associated with obtaining approval for the device from the US Food and Drug Administration (FDA).

MCDC was founded by the joint project manager for Medical Countermeasure Systems.

Its programme provides the country and its military forces with safe, effective, and innovative medical solutions against chemical, biological, radiological and nuclear threats.